GlassScriptPhysician profile
Timothy Weng
NPI 1396438537
$1,965.18
in general payments reported to CMS, 2019-2025
13 companies · $641 in 2025
The $641 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $244 · 2024: $1,080 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $274.99 | 2024-2025 | Rezdiffra |
| Sanofi-Aventis U.S. LLC | $268.91 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $243.65 | 2024 | Jynarque, Rexulti |
| Neurocrine Biosciences, INC. | $135.64 | 2024 | Ingrezza |
| Melinta Therapeutics, LLC | $124.99 | 2025 | Rezzayo |
| Argenx US, INC. | $124.83 | 2025 | Vyvgart |
| Mayne Pharma Commercial LLC | $124.83 | 2024 | |
| Btg International INC. | $123.81 | 2023 | |
| Genzyme Corporation | $120.38 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $117.47 | 2024 | Andexxa |
| Lilly USA, LLC | $116.65 | 2025 | Kisunla |
| Sage Therapeutics, LLC | $95.84 | 2024 | |
| Biogen, INC. | $93.19 | 2024 | Spinraza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Weng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.